新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 9 月 8 日 新疆百花村医药集团股份有限公司 | | | | 新疆百花村医药集团股份有限公司 2025 年第一次临时股东大会议程 3 | | --- | | 议案一：公司关于取消监事会、修订《公司章程》及相关议事规则的议案 4 | | 议案二：公司关于修订公司部分治理制度的议案 49 | | 议案三：公司关于补选董事的议案 63 | 2/63 新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 2025 年第一次临时股东大会议程 （2025 年 9 月 8 日） | 序 号 | 事项 | | --- | --- | | 宣布公司 | 2025 年第一次临时股东大会正式开始 | | 一 | 介绍会议出席情况 | | 二 | 推选计票人及监票人 | | 三 | 宣读并审议议案 | | 1 | 公司关于取消监事会、修订《公司章程》及相关议事规则的议案 | | 2 | 公司关于修订公司部分治理制度的议案 | | 3 | 公司关于补选董事的议案 | | 四 | 与会人员对上述议案进行讨论 ...

上交所公开信息显示，当日该股因日涨幅偏离值达9.60%上榜，营业部席位合计净买入2835.25万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.80亿元，其中，买入成交额为1.04亿 元，卖出成交额为7563.78万元，合计净买入2835.25万元。 百花医药(600721)今日涨停，全天换手率14.63%，成交额5.50亿元，振幅8.24%。龙虎榜数据显示，营 业部席位合计净买入2835.25万元。 百花医药9月1日交易公开信息 资金流向方面，今日该股主力资金净流入8993.68万元，其中，特大单净流入9065.69万元，大单资金净 流出72.01万元。近5日主力资金净流入9254.59万元。 8月22日公司发布的半年报数据显示，上半年公司共实现营业收入2.02亿元，同比增长2.95%，实现净利 润2548.34万元，同比增长12.45%。（数据宝） （文章来源：证券时报网） 具体来看，今日上榜营业部中，第一大买入营业部为开源证券股份有限公司西安西大街证券营业部，买 入金额为2636.16万元，第一大卖出营业部为光大证券股份有限公司南京中山路证券营业部，卖出金额 为1970.10万元。 | ...

Group 1 - The CRO concept sector increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Unimed hitting the daily limit [1] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks exceeding 50 million yuan in net inflow, led by WuXi AppTec with 1.04 billion yuan [2][3] Group 2 - The top stocks by net inflow ratio included Dezhan Health, ST Unimed, and Baohua Pharmaceutical, with net inflow ratios of 26.23%, 17.45%, and 16.34% respectively [3] - The top stocks in the CRO concept by net inflow included WuXi AppTec, Fosun Pharma, and Dezhan Health, with net inflows of 1.04 billion yuan, 233.4 million yuan, and 126.1 million yuan respectively [3][4] - Stocks with significant declines included Sichuan Shuangma, ST Biology, and Hitec Biotech, which fell by 3.73%, 3.03%, and 2.67% respectively [1][6]

Market Overview - On September 1, the medical services sector rose by 3.84%, with Yingkang Life leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Services - Yingkang Life (300143) closed at 12.00, up 12.78% with a trading volume of 544,600 shares and a transaction value of 639 million [1] - Zihua Medicine (600721) closed at 9.85, up 10.06% with a trading volume of 562,700 shares [1] - Innovation Medical (002173) closed at 25.19, up 10.00% with a trading volume of 1,271,700 shares and a transaction value of 3.071 billion [1] - Other notable gainers include Puwis (301257), Baicheng Medicine (301096), and WuXi AppTec (603259) with respective increases of 8.59%, 8.46%, and 8.02% [1] Market Capital Flow - The medical services sector saw a net inflow of 1.699 billion in main funds, while retail funds experienced a net outflow of 1.134 billion [2] - The main funds showed a positive trend in several stocks, particularly WuXi AppTec with a net inflow of 1.087 billion [3] Individual Stock Performance - WuXi AppTec (603259) had a main fund net inflow of 1.087 billion, while retail funds saw a net outflow of 660 million [3] - Innovation Medical (002173) experienced a main fund net inflow of 405 million, with retail funds showing a net outflow of 240 million [3] - Sanbo Brain Science (301293) had a main fund net inflow of 152 million, while retail funds saw a net outflow of 107 million [3]

Market Overview - US and European stock markets experienced a brief rise under the expectation of interest rate cuts by the Federal Reserve, followed by a noticeable stagnation, indicating a range-bound adjustment rather than a head formation [1] - The A-share market remains index-driven, with the number of rising stocks and trading volume failing to keep pace with the upward momentum [1] - Foreign capital continues to have room for increased allocation in the Chinese market, supported by easier overseas liquidity and improving domestic fundamentals [1] Gold Market Insights - Federal Reserve Chairman Jerome Powell indicated rising downside risks in the US job market, suggesting a potential policy shift that could lead to interest rate cuts as early as September [1] - Historical analysis shows that during the last four consecutive rate-cut cycles, gold prices increased by an average of 28%, with a projected 8% rise during the upcoming rate-cut cycle from September to December 2024 [1] - Major financial institutions are bullish on gold prices, with UBS raising its 2026 gold price target to $3,700 per ounce, while Bank of America forecasts a peak of $4,000 per ounce by mid-2026 [3] Sector Performance - The domestic computing power stocks surged, with Data Port hitting the daily limit and several other stocks like Xuanji Information and Huina Technology rising over 5% [4] - Alibaba's recent financial report showed significant growth in capital expenditure and cloud business, with AI-related product revenue achieving triple-digit growth for eight consecutive quarters, leading to a nearly 13% increase in its US stock price [4] - The innovative drug sector saw strong performance, with companies like Maiwei Bio and Baiji Shenzhou hitting historical highs following the announcement of new drug listings by the National Medical Insurance Administration [4] Index Movements - The Shanghai Composite Index opened high and maintained an upward trend, with a focus on whether it can stabilize above 3,880 points [6] - The ChiNext Index opened nearly 2% higher but experienced some pullback, indicating active capital participation and a strong market trend [6] - The China Securities Regulatory Commission expressed a positive outlook on the current market, emphasizing the need to consolidate the recovery momentum and accelerate capital market reforms [6]

来源：上海证券报·中国证券网 上证报中国证券网讯 9月1日，创新药概念股异动拉升，截至9时49分，迈威生物、百花医药涨停，智翔 金泰涨超10%，百济神州涨超7%，股价创历史新高。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开了第九届董事会第六次会议及第九届监事会第五次会议，审议通过了《公 司关于对 2021 年股票期权激励计划股票期权部分予以注销的议案》。 根据《上市公司股权激励管理办法》《公司 2021 年股票期权激励计划（草 案）》相关规定，公司对 2021 年股票期权激励计划首次授予和预留授予激励对 象未达到行权条件的股票期权，合计 74,040 份股票期权进行注销。具体详见公 司于 2025 年 8 月 22 日在上海证券交易所网站（www.sse.com.cn）、上海证券报 和证券日报上披露的《公司关于对 2021 年股票期权激励计划股票期权部分予以 注销的公告》。 公司向中国证券登记结算有限责任公司上海分公司（以下简称"中登公司"） 提交了注销上述股票期权的申请，经中登公司审核确认，上述 74,040 份股票期 权已于 2025 年 8 月 28 日注销完毕。本次股票期权注销对公司总股本不造成影响。 ...

新疆百花村医药集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开了第九届董事会第六次会议及第九届监事会第五次会议，审议通过了《公 司关于对 2021 年股票期权激励计划股票期权部分予以注销的议案》。 根据《上市公司股权激励管理办法》《公司 2021 年股票期权激励计划（草 案）》相关规定，公司对 2021 年股票期权激励计划首次授予和预留授予激励对 象未达到行权条件的股票期权，合计 74,040 份股票期权进行注销。具体详见公 司于 2025 年 8 月 22 日在上海证券交易所网站（www.sse.com.cn）、上海证券报 和证券日报上披露的《公司关于对 2021 年股票期权激励计划股票期权部分予以 注销的公告》。 公司向中国证券登记结算有限责任公司上海分公司（以下简称"中登公司"） 提交了注销上述股票期权的申请，经中登公司审核确认，上述 74,040 份股票期 权已于 2025 年 8 月 28 日注销完毕。本次股票期 ...

Group 1 - The A-share market saw a significant rise in CRO concept stocks, with notable increases in share prices for several companies [1] - Haoyuan Pharmaceutical experienced a rise of over 15%, while Chengdu XianDao and MeidiXi saw increases of over 11% and 10% respectively [1] - Other companies such as Bid Pharma, Boteng Co., and WuXi AppTec also reported gains exceeding 7% [1] Group 2 - The following table summarizes the performance of key CRO stocks, including their percentage increase, total market capitalization, and year-to-date performance [2] - Haoyuan Pharmaceutical: +15.19%, Market Cap: 14.7 billion, YTD: +95.07% - Chengdu XianDao: +11.02%, Market Cap: 10.7 billion, YTD: +116.70% - MeidiXi: +10.54%, Market Cap: 8.75 billion, YTD: +115.91% - Bid Pharma: +8.39%, Market Cap: 5.99 billion, YTD: +36.61% - Boteng Co.: +7.51%, Market Cap: 13.6 billion, YTD: +58.02% - WuXi AppTec: +7.43%, Market Cap: 303.4 billion, YTD: +90.82% - Sunshine Nuohe: +6.32%, Market Cap: 8.46 billion, YTD: +100.86% - Baicheng Pharmaceutical: +4.97%, Market Cap: 6.29 billion, YTD: +51.90% - Kailai Ying: +4.49%, Market Cap: 39 billion, YTD: +43.98% - NuoSiGe: +4.35%, Market Cap: 5.19 billion, YTD: +7.82% [2]

Core Viewpoint - Baihua Pharmaceutical (600721) reported a year-on-year increase in total revenue and net profit for the first half of 2025, indicating stable growth despite a slight decline in quarterly revenue [1] Financial Performance - Total revenue for the first half of 2025 reached 202 million yuan, up 2.95% year-on-year [1] - Net profit attributable to shareholders was 25.48 million yuan, reflecting a 12.46% increase year-on-year [1] - Gross margin improved to 49.4%, an increase of 3.45% year-on-year [1] - Net margin rose to 12.61%, up 9.24% year-on-year [1] - Earnings per share increased to 0.07 yuan, a rise of 11.62% year-on-year [1] Cash Flow and Receivables - Operating cash flow per share was -0.01 yuan, a significant decrease of 108.21% year-on-year [1] - Accounts receivable surged by 216.92%, indicating potential liquidity issues [1][19] - The company reported a 53.63% decrease in cash funds due to investments in bank wealth management products [3] Expense Management - Total selling, administrative, and financial expenses amounted to 34.13 million yuan, accounting for 16.89% of revenue, down 13.28% year-on-year [1] - Selling expenses decreased by 3.24% due to optimized performance assessments [7] - Administrative expenses fell by 12.36% as a result of reduced employee compensation and stock incentive costs [8] Investment and R&D - Development expenditures increased by 27.26% due to capitalized spending on MAH projects [4] - R&D expenses decreased by 12.75%, indicating a reduction in costs during the research phase [10] Tax and Other Financial Metrics - Income tax expenses rose by 137.0% due to increased corporate income tax obligations [14] - The company experienced a 133.82% increase in credit impairment losses, reflecting higher provisions for receivables [11] Market Position and Business Model - The company relies heavily on R&D-driven performance, necessitating careful analysis of underlying drivers [18] - Historical financial performance shows a median ROIC of -1.71% over the past decade, indicating challenges in capital returns [16]